Type 2 Diabetes Therapies (posters)

THR-640

Effectiveness and Safety of Vildagliptin in Addition to Metformin in Elderly (>=70 years) Greek Patients - the Esteem Study
Grigorios Rombopoulos, Elena Panitti, George S Vernikos, Katopodis Panagiotis and Skoutas Dimitrios

THR-641

Effects of Gemigliptin Versus Sitagliptin or Glimepiride on Glycemic Variability As Initial Combination Therapy with Metformin in Drug-Naïve Patients with Type 2 Diabetes
Byung-Wan Lee, Jae Hyeon Kim, Se Eun Park, Chang Hee Jung, Seung-Hwan Lee, Sunghwan Suh, Woo Je Lee, Younghwan Jang, Sung-Ho Kim and Cheol-Young Park

THR-642

Empagliflozin and Linagliptin As Initial Combination for 52 Weeks in Subjects with Type 2 Diabetes
Andrew J Lewin, Ralph DeFronzo, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans-Juergen Woerle and Uli C Broedl

THR-643

Combination of Empagliflozin/Linagliptin for 52 Weeks As Add-on to Metformin in Subjects with Type 2 Diabetes
Sanjay Patel, Andrew J Lewin, Ralph DeFronzo, Dacheng Liu, Renee Kaste, Hans-Juergen Woerle and Uli C Broedl

THR-644

THR-645

Incidence of Adjudicated Acute Pancreatitis Across the Albiglutide Phase 3 Clinical Program
Susan Johnson, Michelle A Anderson, Robert Enns, Jason M Mallory, Margaret Sowell, Tim Wilson and Firas H AL-Kawas

THR-648

Effect of Insulin on Changes in Glycemic Control and Body Weight during Treatment with Exenatide in Patients with Type 2 Diabetes
Maria Batool, Sarah Bellefeuille, Melissa Atwood, Thomas S Rector and Nacide G Ercan-Fang

THR-649

Reversal of Effects of Liraglutide As Additional Treatment to Insulin in Patients with Type 1 Diabetes after Cessation of Therapy
Sophia Y Ali, Aditya Mehta, Nitesh D Kuhadiya, Husam Ghanim, Antoine Makdissi, Manav Batra, Jeanne Hejna, Ajay Chaudhuri and Paresh Dandona

THR-650

Liraglutide Effect in Reducing Hba1c and Weight in Arab Population with Type2 Diabetes, a Prospective Observational Trial. Short Title: Lead-Arab Trial
Alaaeldin Bashier, Azza Abdulaziz Bin Hussain, Elamin Abdelgadir, Ahmed Altinay, Puja Murli Thadani, Fatheya Fardallah Alawadi and Salah Abusnana

THR-653

Canagliflozin Is Superior to Sitagliptin in Reducing Both A1C and Body Weight in Patients with Type 2 Diabetes Mellitus
Jaime A Davidson, Guntram Schernthaner, Laura Hieronymus, Holly Jodon, Ujjwala Vijapurkar, Gary Meininger and William Canovatchel

THR-656

Diabetes Compensation after Changing Injected Sites Because of Detected By Ultrasonography Lipohypertrophy
Natalya Volkova, Ilia Davidenko, Maria Antonenko, Igor Reshetnikov, Aida Gulmagomedova, Irina Dzherieva and Julia Rudakova

THR-659

Shifting to Biosimilar Insulin Preparation: Impact on Glycemic Control and Cost
Charlene Ann Vicencio Balili, Erick Sta. Rosa Mendoza and Leilani Basa Mercado-Asis

THR-663

Demographics and Disease Characteristics in Patients with Type 1 Diabetes Receiving Pramlintide
Amy Kraus, George Serbedzija, Praveen Dhankhar, Taisia Isupov, Alexander Brun and Iftekhar Kalsekar

THR-665

Nutrition Intervention for Diabetic Neuropathy
Anne E Bunner, Cameron L Wells, Elham Bayat and Neal D Barnard

THR-670

Immunogenicity Associated with Metreleptin Treatment in Patients with Obesity or with Lipodystrophy
Jean Lin Chan, Joy Koda, Joseph Heilig, Elaine Cochran, Phillip Gorden, Elif Arioglu Oral and Rebecca J. Brown

THR-671

Antidiabetic and Antilipidemic Properties of Allium Cepa in Streptozotocin-Induced Diabetes
Anthony Emeka Ojieh, Eseroghene Cecilia Adegor, Anthony Chukunweike Okolo, Lawrence Oberhiri Ewhre and Innocent Onyesom

THR-672

The Effects of Amifostine to ACUTE Kidney Injury with Diabetic Ketoacidosis in RATS
Mustafa Unubol, Fatih Firat, Basak Karasu, Ali Akbas, Velid Unsal, Fikret Erdemir, Volkan Yazak, Bilal Acar and Imran kurt Omurlu